Market report: - Intercytex - Early May!

Stem cell; cell based hair therapy
1

Intercytex, up 2p at 62p, is raising £12m by way of a placing of 23.08m shares at 52p each with institutional investors in the UK and Europe. The cell therapy company wants the money to fund the market launch of its first product, Vavelta for facial rejuvenation, and the completion of the Phase Three trial for ICX-PRO.

See link

HOW ABOUT ICX-TRC THEN!

2

This is a good time to buy ICX stock, if they can successfully launch Vavelta for facial rejuvenation their stock price may go up 10-20% or more.

3

» This is a good time to buy ICX stock, if they can successfully launch
» Vavelta for facial rejuvenation their stock price may go up 10-20% or
» more.

What do you base this on? Vavelta will be launched at the end of this year, at the earliest. The stock has gone from 62 to 54 in less than a month. I can almost guarantee that the stock will keep on falling the whole year. All they do is spending money at the moment. My prediction is that the stock will be about 40 p at the end of the year. It is more likely than a 10 % raise at least.
But everyone is free to do whatever they want with their money. I could be wrong.